SLC5A2 and hydrops fetalis: The findings indicated that SGLT2 inhibitors reduced the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95; Q statistic, p = 0.27) and the composite outcome of HF hospitalization or CV death (HR, 0.78; 95% CI, 0.73–0.84; Q statistic, p = 0.09).